Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01087983 · ClinicalTrials.gov registry record · Phase 1
Lapatinib With Sirolimus or Metformin
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 111
- Enrollment target
NCT01087983: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01087983 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 111 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01087983, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 111 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of 2 different combinations of drugs that can be given to patients with advanced cancer. The first combination of drugs is Tykerb (lapatinib) and Rapamune (sirolimus), and the second combination is lapatinib and Glucophage (metformin). The safety of these drug combinations will also be studied.
Interventions
- DRUG Sirolimus
- DRUG Metformin
- DRUG Lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2010-03 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01087983
The ClinicalTrials.gov registry entry for NCT01087983 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sirolimus is the first listed.
NCT01087983 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01087983 about?
NCT01087983 is a clinical study titled "Lapatinib With Sirolimus or Metformin". The goal of this clinical research study is to find the highest tolerable dose of 2 different combinations of drugs that can be given to patients with advanced cancer. The first combination of drugs is Tykerb (lapatinib) and Rapamune (sirolimus), and the second combination is lapatinib and Glucophag...
What is the current status of trial NCT01087983?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 111 participants. The study started on 2010-03. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01087983?
The interventions under investigation include: Sirolimus (DRUG), Metformin (DRUG), Lapatinib (DRUG).
Who is sponsoring clinical trial NCT01087983?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.